Abbisko Therapeutics Co., Ltd (HKG: 2256), a Shanghai-based biotech company, has announced the presentation of Phase II study results for its irpagratinib in combination with atezolizumab for the treatment of advanced hepatocellular carcinoma (HCC) at the 2024 ESMO-GI annual meeting.
Irpagratinib, a novel FGFR4 inhibitor discovered and developed by Abbisko, is combined with atezolizumab, a PD-L1 inhibitor from Swiss pharmaceutical giant Roche. The Phase II trials have demonstrated that the combination of irpagratinib 220mg BID and atezolizumab exhibits outstanding efficacy in HCC patients with FGF19 overexpression, achieving an objective response rate (ORR) of 50%. The treatment combination also showed significant efficacy and a favorable safety profile in patients who have previously received immune checkpoint inhibitors (ICI).- Flcube.com
